Align Technology, Inc. (NASDAQ:ALGN) Shares Bought by Benjamin F. Edwards & Company Inc.

Benjamin F. Edwards & Company Inc. lifted its stake in shares of Align Technology, Inc. (NASDAQ:ALGN) by 8.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 687 shares of the medical equipment provider’s stock after buying an additional 56 shares during the quarter. Benjamin F. Edwards & Company Inc.’s holdings in Align Technology were worth $166,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also made changes to their positions in ALGN. Intech Investment Management LLC boosted its stake in Align Technology by 1,057.3% during the 2nd quarter. Intech Investment Management LLC now owns 12,557 shares of the medical equipment provider’s stock valued at $3,032,000 after acquiring an additional 11,472 shares during the last quarter. First Eagle Investment Management LLC acquired a new stake in shares of Align Technology in the 2nd quarter valued at about $575,000. Seven Eight Capital LP lifted its position in shares of Align Technology by 320.9% during the second quarter. Seven Eight Capital LP now owns 20,542 shares of the medical equipment provider’s stock worth $4,959,000 after purchasing an additional 15,661 shares during the last quarter. Hsbc Holdings PLC grew its stake in Align Technology by 15.8% in the second quarter. Hsbc Holdings PLC now owns 164,637 shares of the medical equipment provider’s stock worth $39,809,000 after purchasing an additional 22,519 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC increased its holdings in Align Technology by 9.1% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 9,148 shares of the medical equipment provider’s stock valued at $2,209,000 after buying an additional 762 shares during the last quarter. Institutional investors own 88.43% of the company’s stock.

Insider Buying and Selling at Align Technology

In other Align Technology news, Director C Raymond Larkin, Jr. purchased 6,500 shares of the firm’s stock in a transaction dated Thursday, August 15th. The stock was bought at an average price of $235.33 per share, with a total value of $1,529,645.00. Following the completion of the purchase, the director now owns 28,247 shares in the company, valued at approximately $6,647,366.51. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.62% of the stock is owned by company insiders.

Align Technology Stock Up 2.9 %

ALGN stock opened at $249.46 on Friday. The stock has a market cap of $18.63 billion, a PE ratio of 41.10, a price-to-earnings-growth ratio of 5.77 and a beta of 1.64. The firm’s 50-day simple moving average is $232.63 and its 200 day simple moving average is $263.34. Align Technology, Inc. has a fifty-two week low of $176.34 and a fifty-two week high of $335.40.

Align Technology (NASDAQ:ALGN) last announced its quarterly earnings results on Wednesday, July 24th. The medical equipment provider reported $2.41 EPS for the quarter, beating the consensus estimate of $2.32 by $0.09. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Align Technology had a net margin of 11.34% and a return on equity of 14.07%. Align Technology’s revenue was up 2.6% compared to the same quarter last year. During the same quarter last year, the business earned $1.73 earnings per share. Equities analysts forecast that Align Technology, Inc. will post 7.61 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on ALGN. Morgan Stanley decreased their target price on Align Technology from $328.00 to $310.00 and set an “overweight” rating for the company in a research report on Thursday, July 25th. Robert W. Baird decreased their price objective on shares of Align Technology from $370.00 to $325.00 and set an “outperform” rating for the company in a report on Monday, July 22nd. Stifel Nicolaus dropped their target price on shares of Align Technology from $400.00 to $350.00 and set a “buy” rating on the stock in a report on Thursday, July 25th. Piper Sandler reaffirmed an “overweight” rating and set a $315.00 price objective on shares of Align Technology in a research report on Friday, September 13th. Finally, StockNews.com upgraded shares of Align Technology from a “hold” rating to a “buy” rating in a research note on Thursday, September 19th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $306.88.

About Align Technology

Align Technology, Inc designs, manufactures, and markets Invisalign clear aligners, and iTero intraoral scanners and services for orthodontists and general practitioner dentists in the United States, Switzerland, and internationally. The company's Clear Aligner segment offers comprehensive products, including Invisalign comprehensive package that addresses the orthodontic needs of younger patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of six and ten years, which is a mixture of primary/baby and permanent teeth.